| Synonym |
| Thai / English name |
Part Used : หัวActivity : CYP1A2 INHIBITIONSolvent/Active Compound : allicinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 98 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 44.22 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 5.14 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 3.52 micromolar lC50 values (micromolar) of test compounds for CYP2D6 inhibition = 47.10 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BzRes) inhibition = 60.10 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 43.73 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : หัวActivity : CYP1A2 INHIBITIONSolvent/Active Compound : dihydromethysticinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 180 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) :Result : PositiveRemark : Results: lC50 values (micromolar) of test compounds for CYP1A2 inhibition = 14.8 micromolar lC50 values (micromolar) of test compounds for CYP2C9 inhibition = 13.35 micromolar lC50 values (micromolar) of test compounds for CYP2C19 inhibition = 0.43 micromolar C50 values (micromolar) of test compounds for CYP2D6 inhibition = 37.03 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BzRes) inhibition = 11.4 micromolar lC50 values (micromolar) of test compounds for CYP3A4 (BFC) inhibition = 2.49 micromolarNote : Evaluated the effects of 25 purified components of commonly used herbal products on the catalytic activity of cDNA-expressed cytochrome P450 isoforms in in vitro experiments. Increasing concentrations of the compounds were incubated with a panel of recombinant human CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4) and their effects on the conversion of specific surrogate substrates measured fluorometrically in a 96-well plate format.
Part Used : น้ำมันActivity : CYP1A2 INHIBITIONSolvent/Active Compound :Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 12 (M/F=6/6)N(Treatment) : 12 (M/F=6/6)Sex : Both sexAge : 67+/-5.2 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg three times dailyDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : CaffeineDose/Conc.(drug) : 100 mgResult : PositiveRemark :Note : Twelve healthy volunteers were randomly assigned to receive each botanical supplement for 28 days followed by a 30-day washout period. Probe drug cocktails of midazolam, caffeine, chlorzoxazone and debrisoquine were administered before (days -1, 0) and at the end of supplementation (days 27, 28). Pre- and post-supplementation phenotypic ratios were determined for CYP3A4, CYP1A2, CYP2E1 and CYP2D6 using 1-hydroxymidazolam/midazolam serum ratios (1-hour), paraxanthine/caffeine serum ratios (6-hour), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour) and debrisoquine urinary recovery ratios (8-hour), respectively.
